ALKS vs LQDA: fair value comparison
Alkermes plc and Liquidia Corporation · Updated 2026-10-19
LQDA's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, LQDA currently ranks higher by quality score.
| ALKS | LQDA | |
|---|---|---|
| Verdict | Overvalued | Awaiting full valuation |
| Last price | $41.22 | $34.35 |
| 12-month range | $27.20–$55.22 | $22.38–$91.03 |
| Rank by discount to fair value | #91 of 108 Healthcare | — |
| Rank by quality score | #48 of 301 Healthcare | #47 of 301 Healthcare |
| Quality grade | B | B |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: ALKS fair value analysis · LQDA fair value analysis